MOTS-c: What Is Being Studied?

MOTS-c is promoted online for metabolism, weight and healthy aging. The research behind it is genuinely interesting, and almost all of it is in mice and cells. This profile explains what has been studied, in whom, and what has not been tested at all. We do not give dosing or usage guidance.

What MOTS-c is

MOTS-c is a peptide of 16 amino acids encoded by a short stretch of DNA inside mitochondria, the energy-producing structures in cells. It was described in 2015 by researchers who reported that its main target appears to be skeletal muscle, where it leads to activation of AMPK, an enzyme that senses cellular energy ^{Source [1]}.

The body makes MOTS-c naturally, and it has been detected in human and rodent blood ^{Source [2]}. Products sold online contain synthetic MOTS-c. As with other research peptides, MOTS-c is a common name rather than an official drug name, and FDA notes that different salt forms, such as the free base and the acetate salt, are sold under it ^{Source [2]}.

What the animal and cell studies report

In the first study, injecting synthetic MOTS-c into mice prevented the weight gain and insulin resistance caused by a high-fat diet, and the insulin resistance that develops with age ^{Source [1]}. A 2021 study from the same research group reported better treadmill performance in young, middle-aged and old mice, and found that treatment started late in life improved physical capacity in old mice. Two of its authors declared consulting and shareholding ties to the company CohBar ^{Source [3]}.

Other rodent and cell studies summarized by FDA report effects on bone-forming cells, bone loss and calcification of blood vessels ^{Source [2]}. FDA adds three caveats. The studies are limited to rodents and have not established dose-response relationships. The molecular target of MOTS-c is unknown, so it is hard to predict which organs it might affect. And in a laboratory test, MOTS-c broke down quickly in human blood, which raises the question of whether MOTS-c given from outside the body could reach active levels at all ^{Source [2]}.

What has been measured in people

Human data so far concern the body's own MOTS-c, not MOTS-c taken as a product. The 2021 study reported that exercise increased natural MOTS-c in human skeletal muscle and blood ^{Source [3]}. A 2025 study of 85 adults found similar blood levels in people with and without obesity, with levels lower at older ages and higher with insulin resistance ^{Source [4]}.

Measurement itself is uncertain. Anti-doping chemists who built a validated mass-spectrometry test could not confirm the natural MOTS-c levels that a commercial immunoassay reported in 20 healthy people, and the two methods gave considerably different results ^{Source [5]}. Studies of natural MOTS-c levels, and any links drawn between those levels and health, should be read with that in mind. Our guide on how to read a peptide study explains why an association in an observational study is not evidence that a product works.

FDA's 2026 review found no clinical studies and no human exposure data for MOTS-c given by any route ^{Source [2]}. A 2026 registry record for a MOTS-c trial comes from a sponsor whose filings include records that describe themselves as fictional examples, so we do not count it as a trial ^{Source [6]}. For how to read registry records, see understanding a clinical trial listing.

Safety

Because it found no human exposure data, FDA describes the potential safety risks of MOTS-c in people as unknown. It also raised concern that a 16-amino-acid peptide given by injection may provoke immune reactions, a risk that aggregation and synthesis impurities can increase ^{Source [2]}.

Regulatory status as of November 3, 2026

MOTS-c is not an FDA-approved drug and is not a component of any approved drug ^{Source [2]}. FDA's page on compounding substances that may present significant safety risks lists it among substances previously in Category 2 whose nominations were withdrawn ^{Source [7]}.

MOTS-c was on the agenda of FDA's July 2026 Pharmacy Compounding Advisory Committee meeting, with obesity and osteoporosis listed as the uses under evaluation ^{Source [8]}. FDA staff concluded there was not enough evidence to evaluate effectiveness and proposed not adding it to the 503A bulks list ^{Source [2]}. According to ABC News, the committee voted to recommend it anyway; the report gave no vote count for MOTS-c. The committee's recommendations are non-binding, and adding a substance to the list requires FDA rulemaking ^{Source [9]}. HHS's October policy document says FDA's drug center recommended against listing either form of MOTS-c and that the committee voted in favor of both ^{Source [10]}; FDA's meeting page listed no minutes or official vote results when we checked on November 3, 2026 ^{Source [8]}.

On October 30, 2026, HHS published notice of a draft interim policy on 503A compounding with certain peptides ^{Source [11]}. The policy's list names six, MOTS-c among them. Until a final rule decides whether MOTS-c goes on the 503A list, HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound MOTS-c acetate in subcutaneous or intramuscular injectable forms, as long as its conditions are met. They include a patient-specific prescription, a single active ingredient, bulk material from an FDA-registered manufacturer with a valid certificate of analysis, and reporting of serious adverse events to FDA ^{Source [10]}. HHS may revisit the policy if a safety signal or product quality problem arises, and the draft is not binding. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are sold ^{Source [11]}. The policy is enforcement discretion, not an approval and not a listing. We found no proposed rule on MOTS-c in the Federal Register as of November 3, 2026.

In sport, the 2026 WADA Prohibited List names MOTS-c as an example of an AMPK activator under S4.4.1, metabolic modulators, which are prohibited at all times ^{Source [12]}.

Research materials and consumer products belong to different categories. A listing, laboratory report, or research-use label does not establish suitability for personal use. The HHS policy concerns pharmacy compounding on a prescription, not products sold as research use only ^{Source [10]}.

Open questions

• Does MOTS-c given from outside the body have any effect in people, by any route?
• Can it reach active levels in the body, given how quickly it breaks down in human blood?
• How reliable are the tests used to measure natural MOTS-c levels?
• What are the risks of repeated injection, including immune responses?